摘要
目的分析使用细胞因子诱导的杀伤细胞(CIK细胞)过继免疫治疗胃癌患者相关临床因素对生存预后的影响。方法入组75例接受CIK细胞治疗的胃癌患者,用淋巴细胞分离液分离出单个核细胞,将诱导培养后的CIK细胞回输给胃癌患者,采用回顾性队列研究,用Kaplan-Meier估计中位生存时间,用Log-rank检验比较临床因素对生存的影响。结果CIK治疗组的复发率明显低于化疗组(53.3%vs.71.6%),差异有统计学意义(χ2=5.566,P=0.018)。CIK治疗组75例胃癌患者的中位生存时间明显高于化疗组(49个月vs.27个月),差异有统计学意义(χ2=10.907,P=0.001)。在CIK治疗组中,肿瘤大小、是否复发、病理分级和肿瘤分期显著影响CIK的生存预后,差异有统计学意义。结论CIK细胞回输治疗可以明显延长胃癌患者的生存期,但其疗效和预后受到相关临床因素的影响。
Objective To analyze correlated clinical factors on the prognosis of gastric cancer patients treated with cytokine-induced killer cells（CIK cells）adoptive immunotherapy.Methods Lymphocyte separation medium was used for the separation of mononuclear cells,and then CIK cells induced and cultured were infused back to gastric cancer patients.Retrospective cohort study was adopted,the median survival time was estimated by Kaplan-Meier method,and the impact on the prognosis of clinical factors were compared by Log-rank test.Results The recurrence rate was significantly lower in CIK treatment group than that in chemotherapy group（53.3% vs.71.6%）,and the difference was statistically significant（χ2=5.566,P=0.018）.The median survival time of gastric cancer patients in CIK treatment group was significantly longer than that in chemotherapy group（49 vs.27 months）,and the difference was statistically significant（χ2=10.907,P=0.001）.In CIK treatment group,the prognosis was significantly affected by tumor size,whether to relapse,pathological grade and tumor stage,and the differences were statistically significant.Conclusion CIK cell transfusion can significantly improve the survival time of gastric cancer patients,and the efficacy and prognosis are affected by correlated clinical factors of gastric cancer patients.
出处
《临床肿瘤学杂志》
CAS
2010年第4期295-299,共5页
Chinese Clinical Oncology
基金
国家自然科学基金项目(30950022
30972703)
江苏省卫生厅医学科技发展基金项目(P200932
P200933)
江苏省卫生厅"科教兴卫工程"江苏省临床免疫学重点实验室开放课题基金项目(KF200972)
常州市社会发展计划项目(CS2008202)
